Homocysteine and asymmetric dimethylarginine concentrations in the plasma of Alzheimer’s disease patients with varying degrees of dementia

Jolanta Dorszewska, Jolanta Florczak-Wyspiańska, Anna Oczkowska, Mateusz Dezor, Michał Prendecki, Wojciech Kozubski

Chair and Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Laboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.

DOI: 10.4236/aad.2013.21001                

Abstract

Alzheimer’s disease (AD) is accompanied by elevated levels of homocysteine (Hcy). Homocysteine may induce elevated concentration of asymmetric dimethylarginine (ADMA). Both Hcy and ADMA are the amino acids thought to represent risk factors of vascular diseases. Studies were conducted on the plasma levels of Hcy and methionine (Met), estimated by HPLC with electrochemical detection, as well as on levels of ADMA and arginine (Arg), estimated by HPLC with fluorescent detection, in the AD patients with benign through to severe dementia estimated by MMSE scale and in a control group. The studies disclosed elevated levels of Hcy and ADMA in AD (Hcy, p < 0.001) as compared to controls, as well as in subjects older than 60 years of age (Hcy, p < 0.01). The AD patients with severe dementia have shown elevated levels of Hcy (p < 0.05) as compared to the patients with moderate dementia. The concentration of Metand Arg showed a downward trend in AD patientswith severe dementia. The highest levels of ADMA have been demonstrated in AD patients in the early stages of the disease. In parallel, in AD with varying degrees of dementia and subjects older than 60 years of age a disturbed turnover was observed of Hcy to Met and of Arg to ADMA. Similarly to Hcy, ADMA seems to be a potential risk factor of AD and important factor for progress of dementia.

Keywords

Homocysteine; ADMA; Dementia; Alzheimer’s Disease

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Seshadri, S., Beiser, A., Selhub, J., Jacques, P.F., Rosenberg, I.H., D’Agostino, R.B., Wilson, P.W. and Wolf, P.A. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. New England Journal of Medicine, 346, 476-483. doi:10.1056/NEJMoa011613
[2]	Styczyńska, M., Strosznajder, J.B., Religa, D., Chodakowska-Zebrowska, M., Pfeffer, A., Gabryelewicz, T., Czapski, G.A., Kobrys, M., Karciauskas, G. and Barcikowska, M. (2008) Association between genetic and environmental factors and the risk of Alzheimer’s disease. Folia Neuropathologica, 46, 249-254. http://goo.gl/XNLdY
[3]	Gary, J.D. and Clarke, S. (1998) RNA and protein interactions modulated by protein arginine methylation. Progress in Nucleic Acid Research and Molecular Biology, 61, 65-131. doi:10.1016/S0079-6603(08)60825-9
[4]	Vallance, P., Leone, A., Calver, A., Collier, J. and Moncada, S. (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 339, 572-575. doi:10.1016/0140-6736(92)90865-Z
[5]	Stuhlinger, M.C., Tsao, P.S., Her, J.H., Kimoto, M., Balint, R.F. and Cooke, J.P. (2001) Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine. Circulation, 104, 2569-2575. doi:10.1161/hc4601.098514
[6]	McGeer, P.L., Itagaki, S., Boyes, B.E. and McGeer, E.G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology, 38, 1285-1291. doi:10.1212/WNL.38.8.1285
[7]	Yoo, J.H. and Lee, S.C. (2001) Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis, 158, 425-430. doi:10.1016/S0021-9150(01)00444-0
[8]	Kielstein, J.T., Bode-Boger, S.M., Frolich, J.C., Ritz, E., Haller, H. and Fliser, D. (2003) Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation, 107, 1891-1895. doi:10.1161/01.CIR.0000060496.23144.A7
[9]	Selley, M.L. (2003) Increased concentration of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer’s disease. Neurobiology of Aging, 24, 903-907. doi:10.1016/S0197-4580(03)00007-1
[10]	McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R. Jr., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S. and Phelps, C.H. (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers and Dementia, 7, 263-269. doi:10.1016/j.jalz.2011.03.005
[11]	Religa, D., Styczynska, M., Peplonska, B., Gabryelewicz, T., Pfeffer, A., Chodakowska, M., Luczywek, E., Wasiak, B., Stepien, K., Golebiowski, M., Winblad, B. and Barcikowska, M. (2003) Homocysteine, apolipoproteine E and methylenetetrahydrofolate reductase in Alzheimer’s disease and mild cognitive impairment. Dementia and Geriatric Cognitive Disorders, 16, 64-70. doi:10.1159/000070677
[12]	Siuda, J., Gorzkowska, A., Patalong-Ogiewa, M., Krzystanek, E., Czech, E., Wiechula, B., Garczorz, W., Danch, A., Jasińska-Myga, B. and Opala, G. (2009) From mild cognitive impairment to Alzheimer’s disease—Influence of homocysteine, vitamin B12 and folate on cognition over time: Results from one-year follow-up. Neurologia i Neurochirurgia Polska, 43, 321-329. http://www.termedia.pl/Czasopismo/-15/Artykul-13058
[13]	Accinni, R., Bartesaghi, S., De Leo, G., Cursano, C.F., Achilli, G., Loaldi, A., Cellerino, C. and Parodi, O. (2000) Screening of homocysteine from newborn blood spots by high-performance liquid chromatography with coulometric array detection. Journal of Chromatography A, 896, 183-189. doi:10.1016/S0021-9673(00)00715-9
[14]	Pi, J., Kumagai, Y., Sun, G. and Shimojo, N. (2000) Improved method for simultaneous determination of L-arginine and its monoand dimethylated metabolites in biological samples by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications, 742, 199-203. doi:10.1016/S0378-4347(00)00145-6
[15]	Dezor, M., Dorszewska, J., Florczak, J., Kempisty, B., Jaroszewska-Kolecka, J., Rozycka, A., Polrolniczak, A., Bugaj, R., Jagodzinski, P.P. and Kozubski, W. (2011) Expression of 8-oxoguanine DNA glycosylase 1 (OGG1) and the level of p53 and TNF-alpha proteins in peripheral lymphocytes of patients with Alzheimer’s disease. Folia Neuropathologica, 49, 123-131. http://goo.gl/JSLhG
[16]	Songin, M., Jesko, H., Czapski, G., Adamczyk, A. and Strosznajder, R.P. (2007) GSK-3beta and oxidative stress in aged brain. Role of poly(ADP-ribose) polymerase-1. Folia Neuropathologica, 45, 220-229. http://goo.gl/KaJpg
[17]	Genedani, S., Rasio, G., Cortelli, P., Antonelli, F., Guidolin, D., Galantucci, M., Fuxe, K. and Agnati, L.F. (2004) Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer’s disease patients and in Parkinson’s disease patients. Neurotoxicity Research, 6, 327-332. doi:10.1007/BF03033443
[18]	Fuso, A., Seminara, L., Cavallaro, R.A., D’Anselmi, F. and Scarpa, S. (2005) S-adenosylmethionine/homocysteine cycle alterations modiify DNA methylation status with consequent deregulation of PS1 and BACE and betaamyloid production. Molecular and Cellular Neuroscience, 28, 195-204. doi:10.1016/j.mcn.2004.09.007
[19]	Borowczyk, K., Tisonczyk, J. and Jakubowski, H. (2012) Metabolism and neurotoxicity of homocysteine thiolactone in mice: Protective role of bleomycin hydrolase. Amino Acids, 43, 1339-1348. doi:10.1007/s00726-011-1207-5
[20]	Boger, R.H., Bode-Boger, S.M., Sydow, K., Heistad, D.D. and Lentz, S.R. (2000) Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocysteinemia or hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1557-1564. doi:10.1161/01.ATV.20.6.1557
[21]	Arlt, S., Schulze, F., Eichenlaub, M., Maas, R., Lehmbeck, J.T., Schwedhelm, E., Jahn, H. and Boger, R.H. (2008) Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 26, 58-64. doi:10.1159/000144026
[22]	Chen, M., Jiang, P., Lu, J., Xiang, Z.H. and Jiao, B.H. (2010) The correlation of asymmetrical dimethylarginine level and oxidative stress to the onset of Alzheimer’s disease. Yao Xue Xue Bao, 45, 1001-1005.
[23]	Kubes, P., Suzuki, M. and Ganger, D.N. (1991) Nitric oxide: An endogenous modulator of leukocyte adhesion. Proceedings of the National Academy of Sciences USA, 88, 4651-4655. doi:10.1073/pnas.88.11.4651
[24]	De la Torre, J.C. (2002) Alzheimer disease as a vascular disorder: Nosological evidence. Stroke, 33, 1152-1162. doi:10.1161/01.STR.0000014421.15948.67
[25]	Su, J.H., Deng, G. and Cotman, C.W. (1997) Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer’s disease brain. Brain Research, 774, 193-199. doi:10.1016/S0006-8993(97)81703-9
[26]	Jonasson, T.F., Hedner, T., Hultberg, B. and Ohlin, H. (2003) Hyperhomocys-teinaemia is not associated with increased levels of asymmetric dimethylarginine in patients with ischaemic heart disease. European Journal of Clinical Investigation, 33, 543-549. doi:10.1046/j.1365-2362.2003.01184.x